Navigation Links
As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Date:3/26/2009

Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources

WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic arthritis and more than 10 percent have altered their prescription patterns for adult rheumatoid arthritis in response to the Food and Drug Administration's (FDA) investigation into the malignancy risk associated with TNF-alpha inhibitors.

In June 2008, the FDA launched an investigation into the malignancy risk associated with TNF-alpha inhibitors in pediatric and juvenile populations being treated for autoimmune diseases. Concerns were raised when 30 cases of cancer in pediatric and juvenile patients being treated for rheumatoid arthritis and Crohn's disease were reported between 1998 and 2008.

The new Physician & Payer Forum report entitled TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns? finds that, of the rheumatologists that have altered their prescription patterns for juvenile idiopathic arthritis, 71 percent say that they prescribe conventional disease-modifying antirheumatic drugs more frequently than they had in the past. Nearly 60 percent of surveyed gastroenterologists say they have altered their prescription patterns for pediatric Crohn's disease -- of these gastroenterologists, 42 percent indicate that they restrict TNF-alpha inhibitors to patients with more severe disease. Furthermore, 45 percent of gastroenterologists say that they have altered their prescribing habits in adult Crohn's disease patients.

The report also finds that one out of five surveyed managed care organization (MCO) pharmacy directors indicate that they will alter their reimbursement of TNF-alpha inhibitors for the treatment of juvenile idiopathic arthritis and pediatric Crohn's disease.

"Twenty percent of surveyed MCO pharmacy directors will alter their reimbursement of TNF-alpha inhibitors for juvenile idiopathic arthritis or pediatric Crohn's disease in the light of the FDA investigation," said Decision Resources Analyst Dancella Fernandes, Ph.D. "MCOs that plan to alter the reimbursement of TNF-alpha inhibitors expect to be more cautious in granting approval, but none cite the intention of routinely refusing reimbursement for autoimmune indications."

TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns? is based on a U.S. survey of 71 rheumatologists, 71 gastroenterologists, and 20 managed care organization (MCO) pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563
    ccomfort@dresources.com                       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cowden Associates Releases Eighth-Annual Employee Benefit Survey Results
2. China Medicine Announces Record Fourth Quarter and 2008 Results
3. Londons First Science-Based Cellulite Massage Guarantees Results for Londons Cellulite Sufferers
4. Boys Skin Care Range Finds Interesting Results
5. Surgical Care Affiliates Announces Investor Conference Call to Discuss 2008 Fourth Quarter and Year-End Results
6. Subtle Fillers Bring Breathtaking Results; The Neigel Center for Cosmetic and Laser Surgery Hosts Its March 27th Filler Day Specials!
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
8. Global Med Technologies(R), Inc. to Report Fourth Quarter and Year End Financial Results Today
9. Discovery may result in new test to determine predisposition to cancer
10. Cord Blood America Announces Results of Shareholder Special Meeting
11. Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
Breaking Medicine Technology: